Pharmacokinetics, pharmacodynamics, and metabolism of triethylenetetramine in healthy human participants: an open-label trial.

@article{Lu2010PharmacokineticsPA,
  title={Pharmacokinetics, pharmacodynamics, and metabolism of triethylenetetramine in healthy human participants: an open-label trial.},
  author={Jun Lu and Sally D Poppitt and Asma A. Othman and Tracey Sunderland and Katya Ruggiero and Michael S. Willett and Lisa E Diamond and Wilfredo D Garcia and Benno G Roesch and Garth J S Cooper},
  journal={Journal of clinical pharmacology},
  year={2010},
  volume={50 6},
  pages={647-58}
}
The selective Cu(II)-chelator, triethylenetetramine (TETA), is undergoing clinical trials for the treatment of heart failure in patients with diabetes. Recently, the authors showed that 2 acetylated metabolites, N(1)-acetyltriethylenetetramine (MAT) and N(1),N(10)-diacetyltriethylenetetramine (DAT), are formed in humans following oral TETA administration. Thus, it became necessary to determine whether the N-acetyltransferase (NAT) 2 phenotype has any effects on the pharmacological properties… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

Similar Papers

Loading similar papers…